WO2003000733A3 - Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis - Google Patents

Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis Download PDF

Info

Publication number
WO2003000733A3
WO2003000733A3 PCT/EP2002/006767 EP0206767W WO03000733A3 WO 2003000733 A3 WO2003000733 A3 WO 2003000733A3 EP 0206767 W EP0206767 W EP 0206767W WO 03000733 A3 WO03000733 A3 WO 03000733A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycopeptides
multiple sclerosis
diagnosis
preparation
therapeutic treatment
Prior art date
Application number
PCT/EP2002/006767
Other languages
French (fr)
Other versions
WO2003000733A2 (en
Inventor
Anna Maria Papini
Mario Chelli
Paolo Rovero
Francesco Lolli
Original Assignee
Univ Firenze
Anna Maria Papini
Mario Chelli
Paolo Rovero
Francesco Lolli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11442221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003000733(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL368158A priority Critical patent/PL207174B1/en
Priority to IL15947902A priority patent/IL159479A0/en
Priority to DE60226324T priority patent/DE60226324T2/en
Priority to US10/482,044 priority patent/US7037893B2/en
Priority to AU2002316989A priority patent/AU2002316989B2/en
Application filed by Univ Firenze, Anna Maria Papini, Mario Chelli, Paolo Rovero, Francesco Lolli filed Critical Univ Firenze
Priority to DK02745396T priority patent/DK1406927T3/en
Priority to EP02745396A priority patent/EP1406927B1/en
Priority to CA2451347A priority patent/CA2451347C/en
Priority to HU0400262A priority patent/HUP0400262A3/en
Publication of WO2003000733A2 publication Critical patent/WO2003000733A2/en
Publication of WO2003000733A3 publication Critical patent/WO2003000733A3/en
Priority to IL159479A priority patent/IL159479A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Glycopeptides capable of identifying multiple sclerosis antibodies, and therefore useful as diagnostic tools or for the treatment of said pathology are described.
PCT/EP2002/006767 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis WO2003000733A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
HU0400262A HUP0400262A3 (en) 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the treatment of multiple sclerosis
IL15947902A IL159479A0 (en) 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
DE60226324T DE60226324T2 (en) 2001-06-22 2002-06-19 GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR TREATMENT OF MULTIPLE SCLEROSIS
US10/482,044 US7037893B2 (en) 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
AU2002316989A AU2002316989B2 (en) 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
PL368158A PL207174B1 (en) 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
DK02745396T DK1406927T3 (en) 2001-06-22 2002-06-19 Glycopeptides, Preparation and Use thereof for Diagnosis or Therapeutic Treatment of Disseminated Sclerosis
EP02745396A EP1406927B1 (en) 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
CA2451347A CA2451347C (en) 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
IL159479A IL159479A (en) 2001-06-22 2003-12-21 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001FI000114A ITFI20010114A1 (en) 2001-06-22 2001-06-22 GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE IN THE DIAGNOSIS OR THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
ITFI2001A000114 2001-06-22

Publications (2)

Publication Number Publication Date
WO2003000733A2 WO2003000733A2 (en) 2003-01-03
WO2003000733A3 true WO2003000733A3 (en) 2003-11-13

Family

ID=11442221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006767 WO2003000733A2 (en) 2001-06-22 2002-06-19 Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis

Country Status (15)

Country Link
US (1) US7037893B2 (en)
EP (1) EP1406927B1 (en)
AT (1) ATE393785T1 (en)
AU (1) AU2002316989B2 (en)
CA (1) CA2451347C (en)
CZ (1) CZ2004122A3 (en)
DE (1) DE60226324T2 (en)
DK (1) DK1406927T3 (en)
ES (1) ES2305258T3 (en)
HU (1) HUP0400262A3 (en)
IL (2) IL159479A0 (en)
IT (1) ITFI20010114A1 (en)
PL (1) PL207174B1 (en)
PT (1) PT1406927E (en)
WO (1) WO2003000733A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010114A1 (en) 2001-06-22 2002-12-22 Univ Firenze GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE IN THE DIAGNOSIS OR THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
ITFI20010144A1 (en) * 2001-07-25 2003-01-25 Univ Firenze COLUMNS FOR IMMUNO ABSORPTION FOR SUBTRACTION OF ANTIBODIES FROM BLOOD WITH SELECTIVE PLASMAFILTRATION TECHNIQUES
MXPA05001270A (en) 2002-08-02 2005-08-03 Glycominds Ltd Method for diagnosing multiple sclerosis.
US8216791B2 (en) 2005-01-31 2012-07-10 Glycominds Ltd. Method for diagnosing multiple sclerosis
US7572592B2 (en) 2005-01-31 2009-08-11 Glycominds Ltd Method for diagnosing multiple sclerosis
WO2008127642A1 (en) * 2007-04-11 2008-10-23 Enteron Limited Partnership Myelin specific ige unencumbered by corresponding blocking antibodies as a causative factor in multiple sclerosis
CN101680883A (en) * 2007-04-12 2010-03-24 艾匹托普国际股份有限公司 Biomarkers for multiple sclerosis
ATE514711T1 (en) 2007-10-16 2011-07-15 Toscana Biomarkers S R L GALACTOSYLATED PEPTIDES, THEIR PREPARATION AND USE FOR DIAGNOSING AUTOIMMUNE DISEASES
US20100203569A1 (en) 2009-02-12 2010-08-12 Glycominks LTD Method for Evaluating Risk in Multiple Sclerosis
ITFI20120164A1 (en) 2012-06-05 2013-12-06 Azienda Ospedaliera Universitaria S Enese 50 NEW GLYCOSYLATED PEPTIDES.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1999057241A2 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
WO2000012126A1 (en) * 1998-08-26 2000-03-09 The Regents Of The University Of California Autoantibody inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010114A1 (en) 2001-06-22 2002-12-22 Univ Firenze GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE IN THE DIAGNOSIS OR THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
ITRM20010408A1 (en) * 2001-07-10 2003-01-10 Univ Napoli Federico Ii CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1999057241A2 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
WO2000012126A1 (en) * 1998-08-26 2000-03-09 The Regents Of The University Of California Autoantibody inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAZZUCCO S ET AL: "A Synthetic Glycopeptide of Human Myelin Oligodendrocyte Glycoprotein To Detect Antibody Responses in Multiple Sclerosis and Other Neurological Diseases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 2, 18 January 1999 (1999-01-18), pages 167 - 172, XP004152593, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2003000733A2 (en) 2003-01-03
IL159479A0 (en) 2004-06-01
CZ2004122A3 (en) 2004-07-14
IL159479A (en) 2010-12-30
PT1406927E (en) 2008-07-31
DE60226324D1 (en) 2008-06-12
EP1406927A2 (en) 2004-04-14
PL368158A1 (en) 2005-03-21
HUP0400262A3 (en) 2008-05-28
ITFI20010114A1 (en) 2002-12-22
ATE393785T1 (en) 2008-05-15
PL207174B1 (en) 2010-11-30
AU2002316989B2 (en) 2006-10-26
ES2305258T3 (en) 2008-11-01
DE60226324T2 (en) 2009-07-09
HUP0400262A2 (en) 2004-08-30
US20040235713A1 (en) 2004-11-25
CA2451347A1 (en) 2003-01-03
DK1406927T3 (en) 2008-08-18
US7037893B2 (en) 2006-05-02
EP1406927B1 (en) 2008-04-30
CA2451347C (en) 2011-07-19

Similar Documents

Publication Publication Date Title
WO2003039462A3 (en) B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
SI1757606T1 (en) Xanthinderivatives for use as medical agents and the preparation thereof
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
MXPA02003027A (en) Method for providing clinical diagnostic services.
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
MXPA03008739A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
AU2001275820A1 (en) Diagnostic agents for the prenatal diagnosis of preterm delivery, fetal infection, and fetal damage, and diagnostic kit containing the same
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
WO2003000733A3 (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
AU2002317172A1 (en) Tools for the diagnosis, molecular definition and development of treatment of chronic inflammatory joint diseases
WO2003084384A3 (en) Diagnosis of flavivirus infection
WO2003057146A3 (en) Novel compositions and methods for cancer
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
IL173546A0 (en) Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
WO2002024738A1 (en) β-CATENIN NUCLEAR LOCALIZED PROTEIN
EP2322559A3 (en) Neoplasm specific antibodies and uses thereof
AU2002306600A1 (en) Sperm protein 17 for the diagnosis and treatment of cancer
AU2002210438A1 (en) Diagnosis of diseases which are associated with cd24
AU1820499A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 159479

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10482044

Country of ref document: US

Ref document number: 2451347

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002745396

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002316989

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2004-122

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002745396

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2004-122

Country of ref document: CZ

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2002745396

Country of ref document: EP